ERBB3 and non-small cell lung carcinoma: Even though preclinical studies like this and others have suggested that ERBB3-mutants may be oncogenic, no responses to neratinib have been observed in patients with ERBB3-mutated tumors (none were NSCLC) included in the SUMMIT trial [157].